Over the past nineteen years, much of the work that's graced Graphica Inc has been about helping people and making a difference on a grand scale. Though we're not always certain whether this work "finds" us, or we "find" it, we are 100% sure it's meant to be. Making a difference brings us joy, which translates to success for both our clients and ourselves and is precisely "why" we do what we do. This month, to illustrate this concept, we introduce to you the Alliance for Children's Therapeutics.
Recently, Seattle Children’s Research Institute and biotechnology company Kineta, Inc. launched the Alliance for Children’s Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis.
Graphica Inc was honored to design both the logo and the website for this alliance.
Bringing together one of the U.S.’s top five pediatric research institutions with a leading biotechnology company, ACT aims to speed development of medicines for children and teens with autoimmune diseases. In 2013, the U.S. Food and Drug Administration (FDA) approved 27 new drugs; just seven new drugs were approved for pediatric use that same year. And of the 55,000 clinical trials conducted between 2005 and 2010, only nine percent were designed for children.
We sincerely hope this alliance and it's innovative funding model will inspire more of its kind and truly make a difference through real advancements for autoimmune diseases in children. We would like to thank Seattle Children's Research Institute and Kineta Inc for choosing Graphica Inc to play a significant role in influencing action towards this important topic, and for allowing us to contribute our passion and excitement to this worthy cause.
Go make a difference!